We found that the DC-SIGNR protein markedly enhanced the migration of the three types of colon cancer cells and that more cells invaded into the MatrigelTM in the DC-SIGNR protein-treated group than in the untreated group (Fig. 2a, b). This evidence concerns the gene CLEC4M and malignant colon neoplasm.